Evidence map›Paper›PMID 37546983›Full record

ArticlebioRxiv : the preprint server for biology2023

Spatial and single-nucleus transcriptomic analysis of genetic and sporadic forms of Alzheimer's Disease.

Emily Miyoshi, Samuel Morabito, Caden M Henningfield, Negin Rahimzadeh, Sepideh Kiani Shabestari, Sudeshna Das, Neethu Michael, Fairlie Reese, Zechuan Shi, Zhenkun Cao and 14 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 19 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors at 1 institution in 1 country.

Emily MiyoshiDepartment of Neurobiology and Behavior, University of California Irvine, Irvine, CA, USA.
Samuel MorabitoInstitute for Memory Impairments and Neurological Disorders (MIND), University of California Irvine, Irvine, CA, USA.
Caden M HenningfieldDepartment of Neurobiology and Behavior, University of California Irvine, Irvine, CA, USA.
Negin RahimzadehInstitute for Memory Impairments and Neurological Disorders (MIND), University of California Irvine, Irvine, CA, USA.
Sepideh Kiani ShabestariDepartment of Neurobiology and Behavior, University of California Irvine, Irvine, CA, USA.
Sudeshna DasDepartment of Neurobiology and Behavior, University of California Irvine, Irvine, CA, USA.
Neethu MichaelDepartment of Neurobiology and Behavior, University of California Irvine, Irvine, CA, USA.
Fairlie ReeseCenter for Complex Biological Systems (CCBS), University of California Irvine, Irvine, CA, USA.
Zechuan ShiDepartment of Neurobiology and Behavior, University of California Irvine, Irvine, CA, USA.
Zhenkun CaoDepartment of Neurobiology and Behavior, University of California Irvine, Irvine, CA, USA.
Vanessa ScarfoneSue and Bill Gross Stem Cell Research Center, University of California Irvine, Irvine, CA, USA.
Miguel A ArreolaDepartment of Neurobiology and Behavior, University of California Irvine, Irvine, CA, USA.
Jackie LuDepartment of Neurobiology and Behavior, University of California Irvine, Irvine, CA, USA.
Sierra WrightInstitute for Memory Impairments and Neurological Disorders (MIND), University of California Irvine, Irvine, CA, USA.
Justine SilvaInstitute for Memory Impairments and Neurological Disorders (MIND), University of California Irvine, Irvine, CA, USA.
Kelsey LeavyInstitute for Memory Impairments and Neurological Disorders (MIND), University of California Irvine, Irvine, CA, USA.
Ira T LottDepartment of Pediatrics, University of California Irvine School of Medicine, Orange, CA, USA.
Eric DoranDepartment of Pediatrics, University of California Irvine School of Medicine, Orange, CA, USA.
William H YongDepartment of Pathology and Laboratory Medicine, University of California Irvine , Irvine, CA, USA.
Saba ShahinDepartment of Neurobiology and Behavior, University of California Irvine, Irvine, CA, USA.
Mari Perez-RosendahlInstitute for Memory Impairments and Neurological Disorders (MIND), University of California Irvine, Irvine, CA, USA.
Elizabeth HeadInstitute for Memory Impairments and Neurological Disorders (MIND), University of California Irvine, Irvine, CA, USA.
Kim N GreenDepartment of Neurobiology and Behavior, University of California Irvine, Irvine, CA, USA.
Vivek SwarupDepartment of Neurobiology and Behavior, University of California Irvine, Irvine, CA, USA.
University of California, Irvine · US

Funding

National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD)U24AG021886 · NIA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI TATIANA M. FOROUD · 2002 to 2026
$119.8M
Project 3: Biomarkers for DS Clinical TrialsU19AG068054 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHRISTIAN, BRADLEY T · 2020 to 2025
$103.7M
UC Irvine MODEL-ADU54AG054349 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI Kim Green · 2017 to 2026
$71.9M
The Alzheimer's Disease Research Center at the University of California, IrvineP30AG066519 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI Mathew Mark Blurton-Jones · 2020 to 2026
$27.9M
Project 3: Neuropathology of the multi-proteinopathy of c9FTD/ALS.P01NS084974 · NINDS · MAYO CLINIC JACKSONVILLE · PI GENDRON, TANIA FRANCE · 2014 to 2024
$17.6M
Training in the Neurobiology of Aging and Alzheimers DiseaseT32AG000096 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI VIVEK SWARUP, Craig E Stark · 1985 to 2026
$9.6M
Dynamic epigenomic landscape of opioid abuse following early-life adversityU01DA053826 · NIDA · UNIVERSITY OF CALIFORNIA-IRVINE · PI Tallie Z. Baram, CHRISTIE D FOWLER · 2022 to 2026
$3.4M
Oligodendrocyte heterogeneity in Alzheimer' s diseaseRF1AG071683 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI SWARUP, VIVEK, ZHANG, JING · 2021 to 2024
$2.2M
Single-cell epigenomic roadmap of Alzheimer's diseaseF31AG076308 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI MORABITO, SAMUEL JOSEPH · 2022 to 2023
$69k
NIA NIH HHS F31 AG076308NIA NIH HHS P30 AG066519NIA NIH HHS RF1 AG071683NIA NIH HHS T32 AG000096NIA NIH HHS U19 AG068054NIA NIH HHS U24 AG021886NIA NIH HHS U54 AG054349NIDA NIH HHS U01 DA053826NINDS NIH HHS P01 NS084974
6 · The paper itself

Abstract

The pathogenesis of Alzheimer's disease (AD) depends on environmental and heritable factors, with remarkable differences evident between individuals at the molecular level. Here we present a transcriptomic survey of AD using spatial transcriptomics (ST) and single-nucleus RNA-seq in cortical samples from early-stage AD, late-stage AD, and AD in Down Syndrome (AD in DS) donors. Studying AD in DS provides an opportunity to enhance our understanding of the AD transcriptome, potentially bridging the gap between genetic mouse models and sporadic AD. Our analysis revealed spatial and cell-type specific changes in disease, with broad similarities in these changes between sAD and AD in DS. We performed additional ST experiments in a disease timecourse of 5xFAD and wildtype mice to facilitate cross-species comparisons. Finally, amyloid plaque and fibril imaging in the same tissue samples used for ST enabled us to directly link changes in gene expression with accumulation and spread of pathology.

Identifiers

PMID37546983
PMCPMC10402031
OpenAlexW4385268379

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.